SAB Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 304.80M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.